[go: up one dir, main page]

BRPI0516737A - method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate - Google Patents

method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate

Info

Publication number
BRPI0516737A
BRPI0516737A BRPI0516737-0A BRPI0516737A BRPI0516737A BR PI0516737 A BRPI0516737 A BR PI0516737A BR PI0516737 A BRPI0516737 A BR PI0516737A BR PI0516737 A BRPI0516737 A BR PI0516737A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
cyclosporine
derivative
hydroxymethylucine
Prior art date
Application number
BRPI0516737-0A
Other languages
Portuguese (pt)
Inventor
Hans Georg Fliri
David Renwick Houck
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of BRPI0516737A publication Critical patent/BRPI0516737A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to cyclosporin derivatives of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus.
BRPI0516737-0A 2004-10-01 2005-09-30 method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate BRPI0516737A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61515204P 2004-10-01 2004-10-01
US70762605P 2005-08-11 2005-08-11
PCT/US2005/035533 WO2006039668A2 (en) 2004-10-01 2005-09-30 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number Publication Date
BRPI0516737A true BRPI0516737A (en) 2008-04-29

Family

ID=36143148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516737-0A BRPI0516737A (en) 2004-10-01 2005-09-30 method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate

Country Status (19)

Country Link
US (2) US20100167996A1 (en)
EP (1) EP1802650B1 (en)
JP (2) JP5139065B2 (en)
KR (1) KR101309409B1 (en)
CN (1) CN101773661B (en)
AT (1) ATE530561T1 (en)
AU (1) AU2005292162B2 (en)
BR (1) BRPI0516737A (en)
CA (1) CA2583494C (en)
DK (1) DK1802650T3 (en)
ES (1) ES2373450T3 (en)
IL (1) IL182315A (en)
MX (1) MX2007003538A (en)
NZ (1) NZ554514A (en)
PL (1) PL1802650T3 (en)
PT (1) PT1802650E (en)
RU (1) RU2399628C2 (en)
SI (1) SI1802650T1 (en)
WO (1) WO2006039668A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
DE602005010607D1 (en) 2004-11-22 2008-12-04 Astellas Pharma Inc Zyklosporinanalog
CA2623865A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EP1931696B1 (en) * 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
KR101273681B1 (en) 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 New cyclic peptide compounds
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
AU2007254148B2 (en) 2006-05-19 2013-02-07 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
KR101089112B1 (en) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. Active electronic management
MX2009003743A (en) * 2006-10-12 2009-06-18 Novartis Ag Use of modified cyclosporins.
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
CN101687012A (en) 2007-05-02 2010-03-31 安斯泰来制药有限公司 New cyclic peptide compounds
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CN102083852A (en) * 2008-06-06 2011-06-01 西尼克斯公司 Cyclosporin analogs and their use in the treatment of HCV infections
CN102164948A (en) 2008-07-30 2011-08-24 伊索技术制药公司 Nonimmunosuppressive cyclosporine analogue molecules
JP5780969B2 (en) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド Cyclosporine A derivative
CA2750227A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
AU2010208071C1 (en) 2009-01-30 2013-06-20 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
JP2013508425A (en) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dosage treatment plan for HCV combination therapy including BI201335, interferon alfa and ribavirin
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US20130029904A1 (en) * 2009-12-18 2013-01-31 Boehringer Ingelheim International Gmbh Hcv combination therapy
US20120010131A1 (en) 2009-12-30 2012-01-12 Scynexis, Inc. Novel cyclosporin analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JP6093307B2 (en) * 2010-12-03 2017-03-08 エス アンド ティー グローバル インク． Novel cyclosporine derivatives for the treatment and prevention of viral infections
KR102011339B1 (en) 2010-12-15 2019-08-16 콘트라빌 파마슈티컬스, 인코퍼레이티드 Cyclosporine analogue molecules modified at amino acid 1 and 3
RU2448690C1 (en) * 2011-03-15 2012-04-27 Открытое акционерное общество "Биосинтез" Solid prolonged-release dosage form of non-steroidal anti-inflammatory drug ketoprofen, method for preparing it
WO2013028615A2 (en) * 2011-08-19 2013-02-28 S&T Golbal Inc. Novel cyclosporin derivatives for the treatment and prevention of viral infections
CA2874548A1 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
SG11201601274QA (en) * 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
WO2016160362A1 (en) 2015-03-31 2016-10-06 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
US10738084B2 (en) * 2015-06-30 2020-08-11 Sentry Therapeutics Limited Macrocycles
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
US12350310B2 (en) 2019-10-12 2025-07-08 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
KR20220158761A (en) 2020-03-26 2022-12-01 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 Preparation of cyclosporine derivatives
KR20230002589A (en) * 2020-04-15 2023-01-05 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 Prevention and treatment of organ damage

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ES2095926T5 (en) * 1990-11-02 2001-02-16 Novartis Ag CYCLOSPORINS
US5863550A (en) * 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
AU2577295A (en) * 1994-06-01 1995-12-21 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
HUP9900405A3 (en) * 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (en) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド Inhibitors of cyclophilin rotamase activity
FR2757520B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2757521B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2757522B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2762843B1 (en) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE69912952T2 (en) * 1998-06-12 2004-09-02 C-Chem Ag cyclosporine
FR2780061B1 (en) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
USRE40987E1 (en) * 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
ES2341534T3 (en) * 2000-07-21 2010-06-22 Schering Corporation PEPTIDES AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE VIRUS OF HEPATITIS C.
KR20040039622A (en) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 Use of 3-position cyclosporin derivatives for hair growth
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CA2623865A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EP1931696B1 (en) * 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
AU2007254148B2 (en) * 2006-05-19 2013-02-07 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
CN102083852A (en) * 2008-06-06 2011-06-01 西尼克斯公司 Cyclosporin analogs and their use in the treatment of HCV infections
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5780969B2 (en) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド Cyclosporine A derivative
MX2011007194A (en) * 2009-01-07 2013-07-12 Scynexis Inc Combination of a cyclosporine derivative and nucleosides for treating hcv.
CA2750227A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Also Published As

Publication number Publication date
RU2399628C2 (en) 2010-09-20
CN101773661B (en) 2013-09-25
JP2012167113A (en) 2012-09-06
CN101773661A (en) 2010-07-14
EP1802650A4 (en) 2008-08-20
ES2373450T3 (en) 2012-02-03
CA2583494A1 (en) 2006-04-13
IL182315A (en) 2013-08-29
ATE530561T1 (en) 2011-11-15
EP1802650B1 (en) 2011-10-26
KR101309409B1 (en) 2013-09-23
JP2008514732A (en) 2008-05-08
IL182315A0 (en) 2007-07-24
JP5139065B2 (en) 2013-02-06
WO2006039668A2 (en) 2006-04-13
PT1802650E (en) 2011-12-30
US20120264679A1 (en) 2012-10-18
PL1802650T3 (en) 2012-04-30
MX2007003538A (en) 2008-01-16
WO2006039668B1 (en) 2007-05-31
CA2583494C (en) 2014-01-21
AU2005292162A1 (en) 2006-04-13
KR20070073841A (en) 2007-07-10
SI1802650T1 (en) 2012-03-30
AU2005292162B2 (en) 2011-11-10
HK1108703A1 (en) 2008-05-16
EP1802650A2 (en) 2007-07-04
RU2007116119A (en) 2008-11-10
NZ554514A (en) 2010-10-29
US20100167996A1 (en) 2010-07-01
WO2006039668A3 (en) 2007-04-19
DK1802650T3 (en) 2012-02-06

Similar Documents

Publication Publication Date Title
BRPI0516737A (en) method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate
EA200971026A1 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
SE0402735D0 (en) Novel compounds
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
PT1404347E (en) 4'-SUBSTITUTED NUCLEOSID FOR THE TREATMENT OF DISEASES MEDIATED BY HEPATITIS C VIRUS
ATE514699T1 (en) SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVES AS KINASE INHIBITORS
EA200971041A1 (en) NEW PEPTIDE HEPATITIS C VIRUS REPLICATION INHIBITORS
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
ATE551060T1 (en) COMPOSITIONS AND METHODS FOR TREATING NEOVASCULAR DISEASES
TW200615266A (en) Organic compounds
EA200970595A1 (en) DERIVATIVES OF SUBSTITUTED INDAZOLS ACTIVE AS KINAZ INHIBITORS
ATE411022T1 (en) PYRIDYLPYRROLE DERIVATIVES AS EFFECTIVE KINASE INHIBITORS
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
DK1427708T3 (en) Amino-phthalazinone derivatives such as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing the same
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EA200870577A1 (en) CONDENSED TRICYCLIC SULPHONAMIDE INHIBITORS GAMMA-SECRETASES
DE602004008959D1 (en) BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE
ATE498630T1 (en) ARYLALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORIN A IN THE TREATMENT AND PREVENTION OF VIRUS INFECTION
ATE546452T1 (en) PYRAZOLOPYRROL DERIVATIVES AS PROTEIN KINASE INHIBITORS
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
DE602005010744D1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AGENTS AGAINST ADIPOSITAS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.